As a project leader, Dr. Geerts is focused on integrating CRISPR/Cas 9 into the Charles River toolbox for supporting drug development programs. She has experience in assay development, drug target validation, and small molecule testing with a wide range of technologies and in various disease areas. She received her PhD degree in neuroscience from the VU University Amsterdam.
LinkedIn:
https://www.linkedin.com/in/liekegeerts/
Articles:
Fail Early, Fail Fast – A Phenotypic Rescue Approach (Drug Discovery World Summer 2019)